# Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD

> **NCT03824795** · PHASE2 · COMPLETED · sponsor: **MGB Biopharma Limited** · enrollment: 34 (actual)

## Conditions studied

- Clostridium Difficile Infection

## Interventions

- **DRUG:** MGB-BP-3

## Key facts

- **NCT ID:** NCT03824795
- **Lead sponsor:** MGB Biopharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-07
- **Primary completion:** 2020-04-03
- **Final completion:** 2020-04-03
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2020-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03824795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03824795, "Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03824795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*